Skip to main content
. 2022 Jan 28;13:811045. doi: 10.3389/fimmu.2022.811045

Figure 2.

Figure 2

The effect of pharmacotherapy on plasma Hsp90 levels in patients with IIM. (A) Plasma Hsp90 levels were increased in both treatment naïve patients with idiopathic inflammatory myopathies (naïve IIM) and patients with short disease duration with recently started pharmacological treatment (early IIM) compared to healthy controls (HC). Horizontal bars represent the median. (B) Upon 6 and 12 months of standard-of-care pharmacotherapy, plasma Hsp90 levels significantly decreased in treatment naïve/early IIM patients. (C) The 12-month change in Hsp90 was associated with the 12-month change in LD levels. (D) Baseline Hsp90 predicted the 6-month change in LD levels. (E) In IIM patients with established disease, ongoing standard-of-care pharmacotherapy resulted in a significant decrease in plasma Hsp90 levels over six months. (F) Baseline Hsp90 levels were able to predict the 6-month change in the levels of LD. The red line and whiskers represent the mean and standard error of the mean (B, E).